Protagonist Therapeutics Inc (PTGX) Stock AnalysisPTGXProtagonist Therapeutics Inc

Protagonist Therapeutics, Inc. is a biopharmaceutical company with a technology platform that enables de novo discovery of peptide therapeutics. The Company's programs fall into three therapeutic areas: inflammation and immunology (I&I), hematology, and metabolic diseases. Its clinical and pre-clinical programs address biologically and commercially validated targets, including IL-17 oral peptide antagonist PN-881, obesity triple agonist peptide PN-477, obesity dual agonist peptide PN-458, oral small molecule hepcidin functional mimetic PN-8047, and IL-4 and amylin programs. The ICOTYDE (icotrokinra) is used for the treatment of moderate-to-severe plaque psoriasis in adults and pediatric patients 12 years of age or older who weigh at least 40 kg and are candidates for systemic therapy or phototherapy. Rusfertide is an investigational injectable mimetic of the natural hormone hepcidin in development for the treatment of the rare blood disorder polycythemia vera (PV). It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

Protagonist Therapeutics Inc is currently a hold. The stock has shown significant volatility, with a 5-day change of -10.42% and a year-to-date increase of +47.68%. Despite a recent profit of $162.8 million in Q2 2026, the RSI is very low at 19.989, indicating potential oversold conditions. However, insider selling has surged by 7175.14%, which raises concerns about the stock's short-term stability. The forward P/E ratio of 36.90 suggests that the stock is still relatively expensive compared to its earnings potential, especially given the recent high volatility in the market.

4 analysts cover PTGX: 4 rate it Buy, 0 Hold and 0 Sell. The average price target is 94.54.